Brief: Intercept Pharmaceuticals And Its Subsidiary Entered Into Two Separate Settlement Agreements With Apotex And Msn

Intercept Pharmaceuticals

27/02/2023 13:29

Feb 27 (Reuters) - Intercept Pharmaceuticals Inc
 ICPT.O :
    * ON FEB 24, CO AND ITS SUBSIDIARY ENTERED INTO TWO SEPARATE
SETTLEMENT AGREEMENTS WITH APOTEX AND MSN
    * GRANTED APOTEX & MSN NON-EXCLUSIVE, NON-SUBLICENSABLE,
NON-TRANSFERABLE, ROYALTY-FREE LICENSES TO COMMERCIALIZE OCALIVA
GENERIC VERSIONS IN U.S.
    * LICENSES TO COMMERCIALIZE GENERIC VERSIONS OF OCALIVA IN
U.S
COMMENCING, RESPECTIVELY, ON SEPT1, 2031, AND JAN 1, 2032
    * PARTIES WILL FILE SETTLEMENT AGREEMENTS WITH FEDERAL TRADE
COMMISSION & DEPARTMENT OF JUSTICE PURSUANT TO APPLICABLE LAW


Further company coverage:  ICPT.O 

 ((Reuters.Briefs@thomsonreuters.com))